Clinical trials: Female Contraception
Contraception, Female Contraception
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear.
- Trial name
- NCT01178125
- Testing
- DR-102
- Where
- 62 sites in United States, Israel
- Volunteers
- 2,858 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.